These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33212094)

  • 1. Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets.
    Dolšak A; Gobec S; Sova M
    Pharmacol Ther; 2021 May; 221():107746. PubMed ID: 33212094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
    Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
    Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase.
    Capece L; Arrar M; Roitberg AE; Yeh SR; Marti MA; Estrin DA
    Proteins; 2010 Nov; 78(14):2961-72. PubMed ID: 20715188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
    Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
    Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase.
    Rafice SA; Chauhan N; Efimov I; Basran J; Raven EL
    Biochem Soc Trans; 2009 Apr; 37(Pt 2):408-12. PubMed ID: 19290871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
    Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
    Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
    Fatokun AA; Hunt NH; Ball HJ
    Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.
    Austin CJ; Rendina LM
    Drug Discov Today; 2015 May; 20(5):609-17. PubMed ID: 25478733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels.
    Biswas P; Dai Y; Stuehr DJ
    Free Radic Biol Med; 2022 Feb; 180():179-190. PubMed ID: 35051612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.
    Winters M; DuHadaway JB; Pham KN; Lewis-Ballester A; Badir S; Wai J; Sheikh E; Yeh SR; Prendergast GC; Muller AJ; Malachowski WP
    Eur J Med Chem; 2019 Jan; 162():455-464. PubMed ID: 30469041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heme-containing enzymes and inhibitors for tryptophan metabolism.
    Yan D; Lin YW; Tan X
    Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDO and TDO as a potential therapeutic target in different types of depression.
    Qin Y; Wang N; Zhang X; Han X; Zhai X; Lu Y
    Metab Brain Dis; 2018 Dec; 33(6):1787-1800. PubMed ID: 30014175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
    Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.